Gilead Sciences, Inc. ([HOST]): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Gilead Sciences, Inc. | Wiener Boerse: GILD B. %. Get the latest Gilead Sciences, Inc. (GILD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively Oppenheimer Cuts Gilead Sciences Price Target to $ From $, Maintains Outperform Rating. 15h ago. MT. UBS Adjusts Gilead Sciences Price Target to $81 From $80, Maintains Neutral Rating. Feb. MT. Fed officials fail to convince investors, who are focused on earnings. Feb. 07 Gilead Sciences Insider Sold Shares Worth $,, According to a Recent SEC Filing MT Feb. Global markets live: Chevron, Expedia, Standard Chartered, Broadcom, Meta Platforms
GILD | Gilead Sciences Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Gilead Sciences, Inc. Lakeside Drive Foster City, CA United States 6[HOST] Sector(s): Healthcare Industry: Drug Manufacturers - General Full Time Employees GILD Capital Priorities (Gilead investor relations) In the last 10 years, Gilead has shrunk its shares outstanding by %. The company initiated its dividend 7 years ago at $ a share and now Biotechnology company Gilead Sciences (NASDAQ:GILD) wasn’t a “Magnificent Seven” company or a darling of the financial markets in Yet, GILD stock deserves a long-overdue rally in 1 day ago · Gilead Sciences. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries GILD. US Pharmaceuticals. Quotes. News. Financials (USD) More Fundamentals * Assessed data. Chart Gilead Sciences, Inc. Duration. Period. Style. Dynamic Chart. Latest news about Gilead Sciences, Inc. More news. Latest transcript on Gilead Sciences, Inc. Gilead Sciences, Inc., Q4 Earnings Call, Feb 06, Gilead Sciences stock recently saw its biggest one-day correction over the past year history. But I think it's overblown. Read on. The stock sell-off due to Trodelvy's trial Gilead Sciences Inc (NASDAQ:GILD) recently announced a dividend of $ per share, payable on , with the ex-dividend date set for As investors look forward to this upcoming Colliers International Group Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CIGI updated stock price target summary
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You …
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: sale of drugs (%): for the treatment of HIV (63% of net sales), COVID (%), hepatitis C virus (%), hepatitis B virus (%) and other (%; primarily Gilead Sciences (GILD %) stock, on the other hand, has underperformed during the same period, falling 30%. What's intriguing about Gilead is that it is also trading at a substantial discount Gilead Sciences stock (symbol: GILD) underwent a total of 5 stock splits. The most recent stock split occured on January 28th, One GILD share bought prior to February 22nd, would equal to 32 GILD shares today. Stock split list. Date Split Multiple Cumulative multiple; x2: x32 Under the terms of the merger agreement entered into in connection with the transaction, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of CymaBay’s common stock at a price of $ per share in cash, which offer price represents a 27 percent premium to CymaBay’s closing